Karyopharm Therapeutics (Karyopharm Therapeutics) EPS (Diluted) : $-1.25 (TTM As of Dec. 2023)

Karyopharm Therapeutics EPS (Diluted) Chart

Karyopharm Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EPS (Diluted)		Get a 7-Day Free Trial					-3.22	-2.72	-1.65	-2.02	-1.25

Karyopharm Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Diluted)	Get a 7-Day Free Trial															-0.43	-0.30	-0.29	-0.30	-0.36

Competitive Comparison of Karyopharm Therapeutics's EPS (Diluted)

For the Biotechnology subindustry, Karyopharm Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Karyopharm Therapeutics's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's PE Ratio falls into.

Karyopharm Therapeutics EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Karyopharm Therapeutics's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Karyopharm Therapeutics's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics  (NAS:KPTI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Karyopharm Therapeutics EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Karyopharm Therapeutics (Karyopharm Therapeutics) Business Description